APOE and Alzheimer disease: Thus, bypassing the need for a heightened immune response among elderly patients (who typically have higher rates of compromised immunity), we propose that, presuming the elimination of off-target effects in future applications, in utero personalized gene therapies or early-stage somatic editing approaches targeting AD-susceptible APOE4 should result in AD-neutral APOE3, the phenotypes of which are well established in children and adults.